<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607540</url>
  </required_header>
  <id_info>
    <org_study_id>PF and esophageal cancer</org_study_id>
    <nct_id>NCT02607540</nct_id>
  </id_info>
  <brief_title>Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer</brief_title>
  <acronym>PFCRTESC</acronym>
  <official_title>Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with
      cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer. But
      in China because of its toxic reaction, most of patients stop the halfway.

      The purpose of this study is to confirm the difference of 2 and 4 cycles of cisplatin plus
      5-fluorouracil in the definitive chemoradiotherapy for esophagus squamous cell carcinoma. A
      total of 210 patients will be accrued from China within 2 years. The primary endpoint is
      overall survival and the secondary endpoints include progression-free survival, response
      rate, pathologic complete response rate and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to recruit the patients who were pathologically confirmed with esophageal squamous
      cell carcinoma from the Oct 2014. The patients will be divided into two groups.Experimental
      group: Two cycles of cisplatin plus 5-fluorouracil concurrent radiotherapy.Control group:Four
      cycles of cisplatin plus 5-fluorouracil and concurrent radiotherapy.To evaluate the overall
      survival of the 2 group. Also observe the patient's progression-free survival, response rate,
      pathologic complete response rate and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival, OS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival,PFS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall remission rate, ORR</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse event,SAE</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, Qol</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate,DCR</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage II Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Two cycles PF-radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
radiotherapy： 50Gy，2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Four cycles PF-radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
radiotherapy： 50Gy，2 Gy/d，5d/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 cycles cisplatin-5-fluorouracil</intervention_name>
    <description>2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.</description>
    <arm_group_label>Two cycles PF-radiotherapy</arm_group_label>
    <other_name>PF 2 cycles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4 cycles cisplatin-5-fluorouracil</intervention_name>
    <description>4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.</description>
    <arm_group_label>Four cycles PF-radiotherapy</arm_group_label>
    <other_name>PF 4 cycles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity</description>
    <arm_group_label>Two cycles PF-radiotherapy</arm_group_label>
    <arm_group_label>Four cycles PF-radiotherapy</arm_group_label>
    <other_name>Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 45-75years old

          -  Histologically proven squamous cell carcinoma of the esophagus the tumor was in
             T2-4N0-2M0

          -  The patients have not received the surgery or chemo-radiotherapy.

          -  Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L,

          -  ALT、AST≤2.5*N,Cr≤1.5*N.

          -  performance status score 0-2

        Exclusion Criteria:

          -  pregnant, lactating women

          -  Oxaliplatin or fluorouracil Allergy or metabolic disorders

          -  Radiotherapy contraindications

          -  History of organ transplantation

          -  Brain metastasis

          -  The peripheral nervous system disorders

          -  Severe infection

          -  Oral capecitabine who have difficulty with,such as dysphagia,The activities of
             digestive ulcer, Gastrointestinal bleeding

          -  Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high
             blood pressure, diabetes.

          -  Other malignant tumor in recent 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanyou Shan, Master</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshan Feng, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiachun Sun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinshuai Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guoqiang Kong, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhi Yuan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruinuo Jia, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Zhou, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Ren, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruina Yang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Wang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongxuan Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Wang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiyuan Song, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weijiao Yin, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yali Zhang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shegan Gao, Doctor</last_name>
    <phone>18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanyou Shan, Master</last_name>
    <phone>18537976669</phone>
    <email>shantanyou@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shegan gao, doctor</last_name>
      <phone>0379 64811906</phone>
      <email>gsg112258@163.com</email>
    </contact>
    <contact_backup>
      <last_name>tanyou shan, master</last_name>
      <phone>0379 64815350</phone>
      <email>shantanyou@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <reference>
    <citation>Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74.</citation>
    <PMID>11870157</PMID>
  </reference>
  <reference>
    <citation>Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999 Sep;17(9):2915-21.</citation>
    <PMID>10561371</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004 Oct;34(10):615-9. Erratum in: Jpn J Clin Oncol. 2005 Feb;35(2):108.</citation>
    <PMID>15591460</PMID>
  </reference>
  <reference>
    <citation>Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):425-33.</citation>
    <PMID>12957254</PMID>
  </reference>
  <reference>
    <citation>Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8.</citation>
    <PMID>17401004</PMID>
  </reference>
  <reference>
    <citation>Shapiro J, ten Kate FJ, van Hagen P, Biermann K, Wijnhoven BP, van Lanschot JJ. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013 Nov;258(5):678-88; discussion 688-9. doi: 10.1097/SLA.0b013e3182a6191d.</citation>
    <PMID>24096766</PMID>
  </reference>
  <reference>
    <citation>Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.</citation>
    <PMID>23585687</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>January 10, 2016</last_update_submitted>
  <last_update_submitted_qc>January 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Esophageal Squamous Cancer</keyword>
  <keyword>Cisplatin-5-fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

